News for Citius Pharmaceuticals Stock (CTXR)

CTXR Stock Price Increases Over 10% Pre-Market: Why It Happened

Pulse2 • 02/22/21

Citius Pharmaceuticals Announces Closing of $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

PRNewsWire • 02/19/21

CTXR Stock: 9 Things to Know About the Biotech Citius Pharma as Shares Surge

InvestorPlace • 02/19/21

CTXR Stock Price Increases Over 25% Pre-Market: Why It Happened

Pulse2 • 02/19/21

Citius Pharmaceuticals Announces $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

PRNewsWire • 02/17/21

Citius Pharmaceuticals Issues Shareholder Letter with Corporate Update on Recent Achievements and Anticipated Milestones for 2021

PRNewsWire • 02/16/21

Citius Pharmaceuticals to Present Update on Mino-Lok and Other Therapies at the Virtual Investor Conferences Small and Microcap Showcase on February 4

PRNewsWire • 02/02/21

Citius Pharmaceuticals Announces Closing of $20.0 Million Private Placement Offering Priced At-the-Market

PRNewsWire • 01/27/21

Citius Holds Webinar Series on Conducting Mino-Lok Phase 3 Trial During COVID-19

PRNewsWire • 12/15/20

Citius Pharmaceuticals Receives FDA Response and Guidance to Pre-IND Consultation Submission for Mino-Wrap

PRNewsWire • 12/09/20

Citius Announces Results of Study that Mino-Lok Eradicates S. aureus Biofilm More Effectively and Expeditiously than Components

PRNewsWire • 11/30/20

Citius Pharmaceuticals to Present at H.C. Wainwright 6th Annual Israel Conference

PRNewsWire • 11/09/20

Citius Pharmaceuticals: Phase 3 Catalyst Countdown And Ready For Take Off

Seeking Alpha • 10/16/20

Citius Pharmaceuticals Signs an Exclusive Worldwide Licensing Agreement with Novellus Therapeutics for Unique iMSC-Therapy for Acute Inflammatory Respiratory Conditions including COVID-19 Related Acute Respiratory Distress Syndrome (ARDS)

PRNewsWire • 10/07/20

Citius's Mino-Lok trial sites resupplied with registration batch product

PRNewsWire • 09/30/20

Citius Pharmaceuticals Reports Positive Results from Recent Data Monitoring Committee Meeting for Mino-Lok Phase 3 Trial

PRNewsWire • 09/29/20

Citius Pharmaceuticals Achieves Chemical Manufacturing and Control Milestones for Mino-Lok®

PRNewsWire • 09/22/20

Citius Files Addendum to Mino-Lok Phase 3 Trial Record Keeping Protocol to Advance Trials with COVID-19 Compliance

PRNewsWire • 09/15/20

Citius Pharmaceuticals to Present at H.C. Wainwright Virtual 22nd Annual Global Investment Conference

PRNewsWire • 09/08/20

Citius Pharmaceuticals Announces Improved Design and Expansion of Intellectual Property for Mino-Wrap

PRNewsWire • 08/26/20

Citius Pharmaceuticals to Present at the MoneyShow Las Vegas Virtual Expo

PRNewsWire • 08/13/20

Citius Pharmaceuticals Announces Closing of $9.6 Million Bought Deal Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares

PRNewsWire • 08/10/20

Citius Pharmaceuticals Increases Previously Announced Bought Deal Offering to $8.4 Million

PRNewsWire • 08/06/20

Citius Pharmaceuticals Announces $6.0 Million Bought Deal Offering

PRNewsWire • 08/05/20

Citius Submits Mino-Wrap Briefing Package to FDA for Pre-IND Consult

PRNewsWire • 08/04/20